Pulmicort Flexhaler

See also: Generic Pulmicort Respules, Generic Pulmicort Turbuhaler

Pulmicort Flexhaler is a brand name of budesonide, approved by the FDA in the following formulation(s):

PULMICORT FLEXHALER (budesonide - powder, metered; inhalation)

• 
  Manufacturer: ASTRAZENECA
  
  Approval date: July 12, 2006
  
  Strength(s): 0.08MG/INH, 0.16MG/INH ^[RLD]

Has a generic version of Pulmicort Flexhaler been approved?

No. There is currently no therapeutically equivalent version of Pulmicort Flexhaler available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pulmicort Flexhaler. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Formulation for inhalation
  Patent 6,027,714
  Issued: February 22, 2000
  Inventor(s): Trofast; Jan
  Assignee(s): Astra Aktiebolag
  A dry powder composition comprising budesonide and a carrier substance, both of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.
  
  Patent expiration dates:
  
  
  • January 9, 2018
    
    ✓ 
    Patent use: MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
    ✓ 
    Drug product
  
  



• 
  Inhalation device
  Patent 6,142,145
  Issued: November 7, 2000
  Inventor(s): Dagsland; Allan & Malmqvist-Granlund; Karin & Virtanen; Risto
  Assignee(s): Astra Aktiebolag
  An inhaler for administering powder by inhalation, including an inhaler body having two ends and a peripheral wall therebetween; an inhalation unit disposed in the inhaler body, the inhalation unit comprising an inhalation channel, the inhalation channel having an air inlet and an outlet; a dosing unit disposed in the inhaler body for providing a dose of powder to the inhalation channel such that a stream of air containing powder may be drawn from the outlet of the inhalation channel on inhalation by a user; a divider having a first surface bounded by a periphery and which substantially closes one end of the inhaler body; a mouthpiece attached to the periphery of the divider, the mouthpiece having a substantially radially directed flange which provides a second surface and which, together with the first surface, defines an air chamber; a first inlet for the air chamber provided in the first surface within the periphery of the divider and in fluid communication with the outlet of the inhalation channel; a second inlet for the air chamber disposed in the first surface within the periphery of the divider and adjacent the first inlet, a stream of supplementary air in use being drawn through the second inlet on inhalation by the user; and a discrete opening in peripheral wall of the inhaler body which is in fluid communication with the second inlet of the air chamber.
  
  Patent expiration dates:
  
  
  • May 8, 2018
    
    ✓ 
    Drug product
  
  



• 
  Formulation for inhalation
  Patent 6,287,540
  Issued: September 11, 2001
  Inventor(s): Trofast; Jan
  Assignee(s): Astra Aktiebolag
  A dry powder composition comprising one more potent pharmaceutically active substances and a carrier substance, all of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.
  
  Patent expiration dates:
  
  
  • January 9, 2018
    
    ✓ 
    Drug product
  
  



• 
  Inhalation device
  Patent 7,143,764
  Issued: December 5, 2006
  Inventor(s): Dagsland; Allan & Virtanen; Risto
  Assignee(s): AstraZeneca AB
  A powder inhaler for administering powder by inhalation which includes: an inhaler body having an opening therein; an inhalation unit disposed in the inhaler body, the inhalation unit including an inhalation channel through which powder is in use inhaled; a dosing unit for providing a dose of powder to the inhalation channel disposed in the inhaler body so as to be rotatable about the central axis thereof, wherein the dosing unit includes a central shaft which is co-axial with the central axis of the inhaler body and has a spiral groove or protrusion on the end face thereof; and an indicating wheel for providing an indication as to the usage of the inhaler disposed in the inhaler body, the indicating wheel having a toothed periphery for engaging the spiral groove or protrusion on the shaft and being disposed such that at least a part thereof is visible through the opening and so as to be rotatable within a diametrical plane containing the central axis of the inhaler body. One side surface of the indicating wheel includes at least one indication which is representative of the usage of the inhaler. In addition, the inhaler body includes a recess in which the opening is provided. The opening allows at least a part of the one side surface of the indicating wheel to be viewed.
  
  Patent expiration dates:
  
  
  • March 13, 2018
    
    ✓ 
    Drug product
  
  

See also...

• Pulmicort Flexhaler Powder Consumer Information (Wolters Kluwer)
• Pulmicort Flexhaler Consumer Information (Cerner Multum)
• Pulmicort Flexhaler Advanced Consumer Information (Micromedex)
• Budesonide Powder Consumer Information (Wolters Kluwer)
• Budesonide Suspension Consumer Information (Wolters Kluwer)
• Budesonide Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Budesonide Consumer Information (Cerner Multum)
• Budesonide inhalation Consumer Information (Cerner Multum)
• Pulmicort Spacer Advanced Consumer Information (Micromedex)
• Rhinocort Turbuhaler Advanced Consumer Information (Micromedex)
• Budesonide Advanced Consumer Information (Micromedex)
• Budesonide Inhalation Advanced Consumer Information (Micromedex)
• Budesonide AHFS DI Monographs (ASHP)